NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis today announced a €1.9 million ($2.5 million) subsidy from the Flemish government for the development of diagnostic cancer tests.

The funding is for a two-year period, during which Biocartis will develop tests to run on its fully automated system. The tests will be directed at the detection of known, validated oncogenes "and allow for more targeted treatment of certain cancers," Biocartis said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.